Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1b/2a Single Ascending Dose Study of a Half-life Extended RSV Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
Madhi SA, Simões EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, Cao X, Maas BM, Zang X, Krick A, Roadcap B, Vora KA, Aliprantis AO, Lee AW, Sinha A. Madhi SA, et al. Among authors: vora ka. J Infect Dis. 2024 Nov 27:jiae581. doi: 10.1093/infdis/jiae581. Online ahead of print. J Infect Dis. 2024. PMID: 39601265
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, Sterling LM, Hunt A, Cox KS, Vora KA, Roadcap BA, Railkar RA, Lee AW, Stoch SA, Lai E. Aliprantis AO, et al. Among authors: vora ka. Clin Pharmacol Drug Dev. 2021 May;10(5):556-566. doi: 10.1002/cpdd.883. Epub 2020 Oct 30. Clin Pharmacol Drug Dev. 2021. PMID: 33125189 Clinical Trial.
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
Maas BM, Lommerse J, Plock N, Railkar RA, Cheung SYA, Caro L, Chen J, Liu W, Zhang Y, Huang Q, Gao W, Qin L, Meng J, Witjes H, Schindler E, Guiastrennec B, Bellanti F, Spellman DS, Roadcap B, Kalinova M, Fok-Seang J, Catchpole AP, Espeseth AS, Stoch SA, Lai E, Vora KA, Aliprantis AO, Sachs JR. Maas BM, et al. Among authors: vora ka. EBioMedicine. 2021 Nov;73:103651. doi: 10.1016/j.ebiom.2021.103651. Epub 2021 Nov 11. EBioMedicine. 2021. PMID: 34775220 Free PMC article.
Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates.
Monslow MA, Elbashir S, Sullivan NL, Thiriot DS, Ahl P, Smith J, Miller E, Cook J, Cosmi S, Thoryk E, Citron M, Thambi N, Shaw C, Hazuda D, Vora KA. Monslow MA, et al. Among authors: vora ka. Vaccine. 2020 Aug 10;38(36):5793-5802. doi: 10.1016/j.vaccine.2020.06.062. Epub 2020 Jul 20. Vaccine. 2020. PMID: 32703745
Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
Chen Z, Cox KS, Tang A, Roman J, Fink M, Kaufhold RM, Guan L, Xie A, Boddicker MA, Mcguinness D, Xiao X, Li H, Skinner JM, Verch T, Retzlaff M, Vora KA. Chen Z, et al. Among authors: vora ka. BMC Infect Dis. 2018 Dec 4;18(1):613. doi: 10.1186/s12879-018-3517-7. BMC Infect Dis. 2018. PMID: 30509199 Free PMC article.
62 results